Close

FDA Warnings on Viekira Pak are Credit-Negative for AbbVie (ABBV) - Moody's

October 23, 2015 2:17 PM EDT

Moody's Investors Service commented that new warnings by the US Food and Drug Administration (FDA) on AbbVie's (NYSE: ABBV) hepatitis C drug Viekira Pak are credit negative because of lower sales potential. There is no impact on AbbVie's Baa1 ratings at this time, and the rating outlook remains negative.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Credit Ratings

Related Entities

Moody's Investors Service